A Phase 4 interventional study of rosiglitazone-metformin and Metformin in Type 2 Diabetes Mellitus, sponsored by GlaxoSmithKline. Completed. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2010-07-27.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.
Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 163rd largest by enrollment of the 287 interventional ones that give a count, is one of 8 that started in 2004, is one of 98 in phase 4, and was the 35th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18–75 · Men only
JW Pharmaceutical · Sites in Korea, Republic of
Ages 19+
University of California, San Francisco · Sites in United States
Ages 10–21 · Healthy volunteers
RenJi Hospital · Sites in China
Ages 18–65
Lille Catholic University · Sites in France
Ages 18–40
By country, each count listing its studies:
Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 40 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
293 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 58 · Phase 2 31 · Phase 3 77 · Phase 4 98
First in 1996; this study’s year is marked. 8 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 84 is close to the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 100 across the 287 interventional studies. Of the 235 that completed or were terminated, 89 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
155 of 293 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
136 studies in Diabetes Mellitus, Type 2 by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 133 finished, 46 (35%) have results posted.
Among the 136 studies in Diabetes Mellitus, Type 2 by GlaxoSmithKline, this one is the 55th largest by enrollment of the 125 interventional ones that give a count, is one of 7 that started in 2004, is one of 23 in phase 4, and was the 25th registered.
GlaxoSmithKline’s Diabetes Mellitus, Type 2 studies by the year they started, since 2000.
7 of the studies testing metformin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02087826Massachusetts General HospitalStudy of Clinical Response to Acute Metformin By Leveraging Evaluations During a Mixed Meal Tolerance Test for Exploring Glycemia and GeneticS | 2026-12 |
| NCT06120881University of California, San FranciscoPrecision Dosing of Metformin in Youth With T2D | 2026-12-31 |
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
| NCT07442006JW PharmaceuticalGlycemic Variability of Combination Therapies in T2DM | 2027-03-31 |
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, from their registry updates:
Among GlaxoSmithKline’s 136 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
It has been shown in previous study that progressive glycemic deterioration was associated with progressive loss of b-cell function, measured by the decrease in plasma insulin levels, irrespective of the therapy used (diet, sulfonylureas or metformin).There is growing evidence that thiazolidinediones could have a positive action on the b-cell function. But it has not yet been demonstrated that they could protect from a deterioration in insulin secretion in the long term. So, it appears interesting to study the long term evolution of the b-cell function and the possible protection with rosiglitazone in patients with type 2 diabetes showing evidence of loss of b-cell function with metformin alone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
EXCLUSION CRITERIA:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug pages: Metformin · Gliclazide
Also known as: rosiglitazone-metformin, Metformin
Median Change From Baseline in the Insulin Secretory Capacity After a 36-month Treatment
Change from baseline in the insulin secretory capacity was measured by the assesment of blood insulin concentrations (conc.) using the hyperglycaemic clamp (HC) technique, per intravenous glucose perfusion by a catheter. Change from baseline for insulin conc peaks (highest conc level) was calculated as the Month 36 value minus the baseline value. Insulin secretion was assessed by calculating AUC during the first 10 minutes of HC (incremental and total AUC0-10 min) and the AUC after the first 10 minutes of the HC (10-180min).
Time frame: Baseline and Month 36
Median Change From Baseline in the Ratio M/I After a 36-month Treatment
Time frame: Baseline and Month 36
Median Change From Baseline in the Insulin Secretion Capacity After an 18-month Treatment
Change from baseline was calculated as the Month 18 value minus the baseline value. Insulin secretion capacity is measured in blood (blood level of insulin) and is a response of the pancreatic beta-cells to hyperglycemia induced by a glucose IV bolus, then infusion. Hyperglycemic clamp (HC) is a reference technique to evaluate the initial and the secondary phases of insulin secretion.
Time frame: Baseline and Month 18
Mean Change From Baseline in HbA1c at Month 36
Change from baseline was calculated as the Month 36 value minus the baseline value. HbA1c levels were measured by blood draw.
Time frame: Baseline and Month 36
Mean Change From Baseline in FBG at Month 36
Change from baseline was calculated as the Month 36 value minus the baseline value. FBG levels were measured by blood draw.
Time frame: Baseline and Month 36
Median Change From Baseline in Insulin Resistance Index (HOMA-IR) After a 36-month Treatment
Time frame: Baseline and Month 36
Median Change From Baseline in Beta Cell Function Index (HOMA-beta) After a 36-month Treatment
Time frame: Baseline and Month 36
Mean Change From Baseline in CPP Total and Incremental AUC T0-T30 After a 36-month Treatment
Time frame: Baseline and Month 36
Mean Change From Baseline in CPP Concentration Peak and Incremental Concentration Peak T0-T30 After a 36-month Treatment
Time frame: Baseline and Month 36
Mean Change From Baseline in Insulin Sensitivity Index at Months 18 and 36
Change from baseline was calculated as the Month 18 and 36 values minus the baseline value. Insulin sensitivity is measured as the quantity of glucose metabolized per unit of plasma insulin concentration.
Time frame: Baseline and Months 18 and 36
| Milestone | Rosiglitazone + Metformin 4 mg/2 g/Day | Gliclazide + Metformin 80 mg/2 g/Day |
|---|---|---|
| Started | 43 | 41 |
| Completed | 32 | 30 |
| Not completed | 11 | 11 |
| Withdrew: Adverse event | 6 | 3 |
| Withdrew: Patient's willing | 3 | 2 |
| Withdrew: Lack of efficacy | 1 | 2 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Stopping criterion met | 0 | 1 |
| Withdrew: Participant living too far from hospital | 0 | 1 |
Change from baseline in the insulin secretory capacity was measured by the assesment of blood insulin concentrations (conc.) using the hyperglycaemic clamp (HC) technique, per intravenous glucose perfusion by a catheter. Change from baseline for insulin conc peaks (highest conc level) was calculated as the Month 36 value minus the baseline value. Insulin secretion was assessed by calculating AUC during the first 10 minutes of HC (incremental and total AUC0-10 min) and the AUC after the first 10 minutes of the HC (10-180min).
| picomoles/L per minute (pmol/L*min) | Rosiglitazone + Metformin 4 mg/2 g/Day | Gliclazide + Metformin 80 mg/2 g/Day |
|---|---|---|
| Total AUC(0-10 min), n=24, 26 | -3.9 (-688.3 to 2211.2) | -75.3 (-919.9 to 1507.1) |
| Incremental AUC(0-10 min), n=22, 23 | 7.0 (-308.3 to 2781.2) | 74.6 (-822.2 to 1193.8) |
| Total concentration peak(0-10 min), n=25, 26 | -8.6 (-89.6 to 386.5) | 3.6 (-121.2 to 52.3) |
| Incremental concentration peak(0-10 min), n=24, 26 | -1.8 (-60.9 to 443.8) | 10.8 (-128.3 to 56.6) |
| Total AUC(10-180 min), n=20, 24 | 40.6 (-411.9 to 500.2) | -21.2 (-344.2 to 787.3) |
| Incremental AUC(10-180 min), n=19, 24 | 67.0 (-304.2 to 518.4) | 13.6 (-264.9 to 793.4) |
| Total concentration peak(10-180 min), n=27, 29 | 7.9 (-223.0 to 286.1) | -9.3 (-120.5 to 229.4) |
| Incremental concentation peak(10-180 min), n=25,29 | 10.8 (-232.3 to 198.6) | 11.5 (-116.9 to 231.6) |
Results for this outcome have not been posted.
Change from baseline was calculated as the Month 18 value minus the baseline value. Insulin secretion capacity is measured in blood (blood level of insulin) and is a response of the pancreatic beta-cells to hyperglycemia induced by a glucose IV bolus, then infusion. Hyperglycemic clamp (HC) is a reference technique to evaluate the initial and the secondary phases of insulin secretion.
| pmol/L*min | Rosiglitazone + Metformin 4 mg/2 g/Day | Gliclazide + Metformin 80 mg/2 g/Day |
|---|---|---|
| HC, Total AUC(0-10min), n=30, 31 | 18.3 (-1044.7 to 2211.2) | -32.3 (-919.9 to 1612.5) |
| HC, Incremental AUC(0-10min), n=27, 26 | 22.3 (-308.3 to 2781.2) | 60.7 (-822.2 to 1193.8) |
| HC, Total AUC(10-180min), n=26, 30 | 55.9 (-411.9 to 500.2) | -7.6 (-344.2 to 787.3) |
| HC, Incremental AUC(10-180min), n=26, 29 | 72.9 (-304.2 to 518.4) | 14.6 (-264.9 to 1172.7) |
| Arginine (Arg) test, Total AUC(0-30min), n=25, 25 | 38.4 (-367.0 to 225.0) | 10.9 (-163.9 to 93.1) |
| Arg test, Incremental AUC(0-30min), n=25, 25 | 15.1 (-440.3 to 120.9) | -8.0 (-153.3 to 49.3) |
| Arg test, Incremental Conc. peak(0-30 min),n=26,29 | 23.3 (-2531.7 to 766.5) | -111.1 (-1125.0 to 499.7) |
Change from baseline was calculated as the Month 36 value minus the baseline value. HbA1c levels were measured by blood draw.
| percent change | Rosiglitazone + Metformin 4 mg/2 g/Day | Gliclazide + Metformin 80 mg/2 g/Day |
|---|---|---|
| Mean Change From Baseline in HbA1c at Month 36 | -0.22 ± 1.3 | 0.3 ± 1.2 |
Change from baseline was calculated as the Month 36 value minus the baseline value. FBG levels were measured by blood draw.
| millimoles per Liter (mmol/L) | Rosiglitazone + Metformin 4 mg/2 g/Day | Gliclazide + Metformin 80 mg/2 g/Day |
|---|---|---|
| Mean Change From Baseline in FBG at Month 36 | -1.6 ± 1.9 | -0.2 ± 2.4 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Change from baseline was calculated as the Month 18 and 36 values minus the baseline value. Insulin sensitivity is measured as the quantity of glucose metabolized per unit of plasma insulin concentration.
| micromoles (umol)/kilogram/min/pmol/L | Rosiglitazone + Metformin 4 mg/2 g/Day | Gliclazide + Metformin 80 mg/2 g/Day |
|---|---|---|
| Month 18 | -0.00511 ± 0.03451 | -0.02045 ± 0.05302 |
| Month 36 | 0.00040 ± 0.04722 | -0.01702 ± 0.05109 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rosiglitazone + Metformin 4 mg/2 g/Day | — | 8/43 (18.6%) | 31/43 (72.1%) |
| Gliclazide + Metformin 80 mg/2 g/Day | — | 12/41 (29.3%) | 29/41 (70.7%) |
| Event | Rosiglitazone + Metformin 4 mg/2 g/Day | Gliclazide + Metformin 80 mg/2 g/Day |
|---|---|---|
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/43 | 3/41 |
| Peritoneal carcinomatosisNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/43 | 2/41 |
| Oedematous pancreatitisGastrointestinal disorders | 0/43 | 1/41 |
| Partial bowel obstructionGastrointestinal disorders | 0/43 | 1/41 |
| ProctorrhagiaGastrointestinal disorders | 0/43 | 1/41 |
| Umbilical herniaGastrointestinal disorders | 0/43 | 1/41 |
| Spinal column stenosisMusculoskeletal and connective tissue disorders | 0/43 | 1/41 |
| Trigger fingerMusculoskeletal and connective tissue disorders | 0/43 | 1/41 |
| Carpal tunnel syndromeNervous system disorders | 0/43 | 1/41 |
| HemiplegiaNervous system disorders | 0/43 | 1/41 |
| Event | Rosiglitazone + Metformin 4 mg/2 g/Day | Gliclazide + Metformin 80 mg/2 g/Day |
|---|---|---|
| NasopharyngitisRespiratory, thoracic and mediastinal disorders | 9/43 | 3/41 |
| HypoglycemiaMetabolism and nutrition disorders | 1/43 | 8/41 |
| BronchitisRespiratory, thoracic and mediastinal disorders | 8/43 | 1/41 |
| TendonitisMusculoskeletal and connective tissue disorders | 1/43 | 4/41 |
| Carpal tunnel syndromeNervous system disorders | 1/43 | 4/41 |
| LumbagoMusculoskeletal and connective tissue disorders | 4/43 | 1/41 |
| Knee painMusculoskeletal and connective tissue disorders | 2/43 | 3/41 |
| DiarrheaGastrointestinal disorders | 3/43 | 3/41 |
| Fungal infectionInfections and infestations | 0/43 | 3/41 |
| RhinitisInfections and infestations | 0/43 | 3/41 |
| Age Continuous(years) | Rosiglitazone + Metformin 4 mg/2 g/Day | Gliclazide + Metformin 80 mg/2 g/Day | Total |
|---|---|---|---|
| Mean | 58.3 ± 8.4 | 58.1 ± 8.0 | 58.2 ± 8.2 |
| Sex: Female, Male(Participants) | Rosiglitazone + Metformin 4 mg/2 g/Day | Gliclazide + Metformin 80 mg/2 g/Day | Total |
|---|---|---|---|
| Female | 11 | 16 | 27 |
| Male | 32 | 25 | 57 |
| Body Mass Index (BMI)(kilograms per square meter (kg/m2)) | Rosiglitazone + Metformin 4 mg/2 g/Day | Gliclazide + Metformin 80 mg/2 g/Day | Total |
|---|---|---|---|
| <25 | 3 | 0 | 3 |
| 25-30 | 21 | 20 | 41 |
| >30 | 19 | 21 | 40 |
| FBG(Millimoles/Liter (mmol/L)) | Rosiglitazone + Metformin 4 mg/2 g/Day | Gliclazide + Metformin 80 mg/2 g/Day | Total |
|---|---|---|---|
| Mean | 9.10 ± 1.72 | 8.28 ± 1.11 | 8.70 ± 1.50 |
| HbA1c(percentage) | Rosiglitazone + Metformin 4 mg/2 g/Day | Gliclazide + Metformin 80 mg/2 g/Day | Total |
|---|---|---|---|
| Mean | 7.5 ± 0.55 | 7.3 ± 0.55 | 7.4 ± 0.57 |
No study locations are listed for this record.
The record gives a start of Oct 2004, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2009, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Metformin · Gliclazide